Fast onset of action of glycopyrronium compared with tiotropium in patients with moderate to severe COPD — A randomised, multicentre, crossover trial

Short-term benefit of smoking cessation along with glycopirronium on lung function and respiratory symptoms in mild COPD patients: a retrospective study

“…We have used a single bronchodilator in mild COPD according to the GOLD guidelines [21][22][23]. The recent patent, anti-muscarinic glycopirronium, has demonstrated superiority over tiotropium in monotherapy in terms of an increae in FEV1, also demonstrating signifcant benefits when combined with the β-adrenergic agonist indacaterol [24][25][26][27]. The use of glycopirronium in COPD patients over a period of four years brought about a reduction of exacerbations and a reduction of FEV1, significantly reducing hyperinflation and dyspnea in severe and very severe COPD patients [25][26][27].…”

“…The recent patent, anti-muscarinic glycopirronium, has demonstrated superiority over tiotropium in monotherapy in terms of an increae in FEV1, also demonstrating signifcant benefits when combined with the β-adrenergic agonist indacaterol [24][25][26][27]. The use of glycopirronium in COPD patients over a period of four years brought about a reduction of exacerbations and a reduction of FEV1, significantly reducing hyperinflation and dyspnea in severe and very severe COPD patients [25][26][27]. Furthermore, glycopyrronium combined with indacaterol has been extensively studied over the last few years and also more recently in a large trial [23,27,28].…”

“…The use of glycopirronium in COPD patients over a period of four years brought about a reduction of exacerbations and a reduction of FEV1, significantly reducing hyperinflation and dyspnea in severe and very severe COPD patients [25][26][27]. Furthermore, glycopyrronium combined with indacaterol has been extensively studied over the last few years and also more recently in a large trial [23,27,28]. The activity of glycopirronium was also recently evaluated in triple association (beclometasone-formoterol-glycopirronium) compared with double association (indacaterol-glycopirronium), having the rate of severe COPD exacerbations as an endpoint.…”

Comparative Study on the effectiveness of Glycopyrrolate/Formoterol versus Tiotropium/Formoterol in patients with Chronic Obstructive Pulmonary Disease

“…Larger clinical trials have also reported similar results [ 11 , 17 ]. Studies have also reported glycopyrrolate to have a faster onset of action when compared to tiotropium but this was not evident on repeated administration of dose [ 18 , 19 ].…”

Fixed-Dose Combinations of Long-Acting Bronchodilators for the Management of COPD: Global and Asian Perspectives

“…The FAST study characterized the earlier onset of action associated with glycopyrronium; it was superior to tiotropium in terms of early bronchodilation. Both glycopyrronium and tiotropium showed similar improvements in static lung volume parameters; glycopyrronium reduced specific airway resistance faster than tiotropium [64]. In clinical studies of 6–12 months’ duration in patients with moderate-to-severe COPD, glycopyrronium improved lung function, reduced breathlessness, improved symptoms, and reduced moderate-to-severe exacerbations to a similar extent as tiotropium [65].…”